1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Cancer Analysis & Statistics in European Union, July 2020

Cancer Analysis & Statistics in European Union, July 2020

Customer Support

Talk to Ahmad

+1 718 618 4302

All regions

1-30 of about 100 reports

Stivarga

  • $ 10000
  • September 2019
  • 30 pages

Drug Overview Stivarga (regorafenib; Bayer/Amgen) is an orally available small molecule inhibitor that is currently approved for the treatment of previously treated hepatocellular carcinoma patients. It ...

  • Cancer
  • Colorectal Cancer
  • Hepatitis
  • Pathology
  • European Union

Nexavar

  • $ 10000
  • September 2019
  • 28 pages

Drug Overview Nexavar (sorafenib; Bayer/Amgen) is an orally available, multi-targeted tyrosine kinase inhibitor that is directed against several targets, including CRAF, BRAF, RET, KIT, FMS-like tyrosine ...

  • Cancer
  • Hepatitis
  • Renal Cancer
  • European Union
  • United States

Lenvima

  • $ 10000
  • September 2019
  • 29 pages

Drug Overview Lenvima (lenvatinib; Eisai/Merck and Co) is an orally available small molecule inhibitor of multiple tyrosine kinases, including vascular endothelial growth factor receptor (VEGFR), platelet-derived ...

  • Cancer
  • Hepatitis
  • Pathology
  • Renal Cancer
  • European Union

Tecentriq

  • $ 10000
  • September 2019
  • 114 pages

Drug Overview Tecentriq (atezolizumab; Roche/Chugai) is a fully humanized monoclonal antibody that targets programmed death-ligand 1 (PD-L1). PD-L1 is expressed on the surface of antigen-presenting cells ...

  • Cancer
  • Pathology
  • European Union
  • United States
  • Demand

Opdivo

  • $ 10000
  • September 2019
  • 118 pages

Drug Overview Opdivo (nivolumab; Bristol-Myers Squibb/Ono Pharmaceutical) is a fully human immunoglobulin G4 PD-1 immune checkpoint inhibitor that binds to the checkpoint receptor PD-1 expressed on activated ...

  • Cancer
  • Pathology
  • European Union
  • Japan
  • United States

Cyramza

  • $ 10000
  • September 2019
  • 65 pages

Drug Overview Cyramza (ramucirumab; Eli Lilly) is a fully human vascular endothelial growth factor receptor (VEGFR)-2-directed immunoglobulin G1 monoclonal antibody that binds to the extracellular domain ...

  • Cancer
  • Hepatitis
  • Pathology
  • European Union
  • Japan

Imfinzi

  • $ 10000
  • September 2019
  • 57 pages

Drug Overview Imfinzi (durvalumab; AstraZeneca) is a human monoclonal antibody directed against programmed death-ligand 1 (PD-L1). The interaction between PD-L1 and its receptor, programmed death-1 (PD-1), ...

  • Cancer
  • Hepatitis
  • Lung Cancer
  • European Union
  • Demand

Keytruda

  • $ 10000
  • September 2019
  • 141 pages

Drug Overview Keytruda (pembrolizumab; Merck and Co) is a humanized monoclonal antibody designed to inhibit the PD-1 co-inhibitory receptor. The interaction between PD-1 and its primary ligand, PD-L1, ...

  • Cancer
  • Pathology
  • European Union
  • Japan
  • United States

Cabometyx

  • $ 10000
  • September 2019
  • 29 pages

Drug Overview Cabometyx (cabozantinib; Exelixis/Ipsen/Takeda) is an orally available small molecule inhibitor which has been shown to suppress tumor growth and metastasis by inhibiting the activity of ...

  • Cancer
  • Hepatitis
  • Renal Cancer
  • European Union
  • Supply

Votrient

  • $ 10000
  • March 2019
  • 21 pages

Votrient (pazopanib; Novartis) is an oral angiogenesis inhibitor targeting the vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), and c-KIT. Preclinical ...

  • Cancer
  • Pathology
  • Renal Cancer
  • European Union
  • Japan

Torisel

  • $ 10000
  • March 2019
  • 24 pages

Torisel (temsirolimus; Pfizer) is an inhibitor of mammalian target of rapamycin (mTOR), which is an intracellular protein that has been implicated in multiple growth-related cellular functions.

  • Cancer
  • Lymphoma
  • Pathology
  • Renal Cancer
  • European Union

Sutent

  • $ 10000
  • March 2019
  • 19 pages

Sutent (sunitinib; Pfizer) is an orally available multi-targeted tyrosine kinase inhibitor which specifically inhibits vascular endothelial growth factor receptor (VEGFR), platelet-derived growth facto ...

  • Cancer
  • Renal Cancer
  • Therapy
  • European Union
  • Japan

Avastin

  • $ 10000
  • March 2019
  • 111 pages

Avastin (bevacizumab; Genentech/Roche/Chugai) is a humanized immunoglobulin G1 monoclonal antibody directed against vascular endothelial growth factor (VEGF).

  • Cancer
  • Pathology
  • European Union
  • Japan
  • United States

Afinitor

  • $ 10000
  • March 2019
  • 30 pages

Afinitor (everolimus; Novartis) is an orally available analog of the mammalian target of rapamycin (mTOR), which mediates the signal transduction pathways required for cell cycle progression from G1 to ...

  • Breast Cancer
  • Cancer
  • Pathology
  • Renal Cancer
  • European Union

Inlyta

  • $ 10000
  • March 2019
  • 20 pages

Inlyta (axitinib; Pfizer) is a kinase inhibitor designed to selectively inhibit vascular endothelial growth factor receptor-1.

  • Cancer
  • Pathology
  • Renal Cancer
  • European Union
  • Japan

CB-839

  • $ 10000
  • March 2019
  • 14 pages

Drug Overview Cancer cells are known to rely on glycolysis as an energy source. CB-839 (Calithera Biosciences) inhibits the glutaminase enzyme, reducing the ability of cancer cells to utilize glutamine ...

  • Cancer
  • Renal Cancer
  • Therapy
  • European Union
  • Market Description

Renal cell cancer (RCC) disease forecast and market analysis to 2038

  • $ 22000
  • March 2019
  • 578 pages

DISEASE OVERVIEW Renal cell carcinoma (RCC) is a tumor that originates in the renal cortex, the outer part of the kidney between the renal capsule and the renal medulla. Around 85% of all malignant kidney ...

  • Cancer
  • Pathology
  • Renal Cancer
  • European Union
  • United States

Copiktra

  • $ 10000
  • January 2019
  • 26 pages

Drug Overview Copiktra (duvelisib; Verastem/Yakult Honsha) is a highly selective small molecule inhibitor of the p110-delta and p110-gamma isoforms of the phosphoinositide 3-kinase (PI3K) enzyme. The PI3K-delta ...

  • Cancer
  • Lymphoma
  • Pathology
  • European Union
  • United States

Zanubrutinib

  • $ 10000
  • January 2019
  • 23 pages

Drug Overview Zanubrutinib (BeiGene) is an oral small molecule inhibitor of Bruton’s tyrosine kinase (BTK), developed to be more selective with less off-target effects than Imbruvica (ibrutinib; AbbVie/Johnson ...

  • Cancer
  • Lymphoma
  • Pathology
  • European Union
  • United States

Betalutin

  • $ 10000
  • January 2019
  • 17 pages

Drug Overview Betalutin is a first-in-class antibody-radionucleotide conjugate targeted to CD37, an alternative to CD20, which is widely targeted in non-Hodgkin’s lymphoma. CD37 is highly expressed in ...

  • Cancer
  • Lymphoma
  • Pathology
  • European Union
  • United States

Aliqopa

  • $ 10000
  • January 2019
  • 18 pages

Drug Overview Aliqopa (copanlisib; Bayer) is a small molecule phosphoinositide 3-kinase (PI3K) inhibitor with high selectivity for the p110-alpha/delta catalytic subunits. The PI3K pathway is crucial fo ...

  • Cancer
  • Lymphoma
  • Pathology
  • Therapy
  • European Union

Kymriah

  • $ 10000
  • January 2019
  • 38 pages

Drug Overview Kymriah (tisagenlecleucel; Novartis) is a cluster of differentiation (CD)19-targeted genetically modified autologous T-cell immunotherapy, comprised of a murine single-chain antibody fragment ...

  • Cancer
  • Lymphoma
  • Medical Biotechnology
  • Pathology
  • European Union

Venclexta

  • $ 10000
  • January 2019
  • 45 pages

Drug Overview Venclexta (venetoclax; AbbVie/Roche) is an inhibitor of the B-cell lymphoma-2 (BCL-2) family of proteins. This family of proteins is responsible for the regulation of cell death by eithe ...

  • Cancer
  • Leukemia
  • Pathology
  • European Union
  • United States

Zydelig

  • $ 10000
  • January 2019
  • 29 pages

Drug Overview Zydelig (idelalisib; Gilead) is an oral, highly selective inhibitor of the phosphoinositide 3-kinase (PI3K) isoform p110-delta. In vitro studies have demonstrated that Zydelig results in ...

  • Cancer
  • Lymphoma
  • Pathology
  • European Union
  • United States

Treanda/Bendeka

  • $ 10000
  • January 2019
  • 58 pages

Drug Overview Treanda (bendamustine; Teva/Mundipharma/Eisai) is an intravenous cytotoxic agent. The exact mechanism of action of the drug is still not fully known, but it is a mechlorethamine derivative ...

  • Cancer
  • Lymphoma
  • Pathology
  • European Union
  • United States

Rituxan

  • $ 10000
  • January 2019
  • 82 pages

Drug Overview Rituxan (rituximab; Biogen/Roche/Chugai/Zenyaku Kogyo) is a murine/human chimeric cluster of differentiation (CD)20-targeted monoclonal antibody that is indicated for the treatment of a numbe ...

  • Cancer
  • Lymphoma
  • Pathology
  • European Union
  • United States

Imbruvica

  • $ 10000
  • January 2019
  • 51 pages

Drug Overview Imbruvica (ibrutinib; AbbVie/Johnson and Johnson) is an oral small molecule inhibitor of Bruton’s tyrosine kinase (BTK). BTK is part of the B-cell receptor signaling pathway, which promotes ...

  • Cancer
  • Lymphoma
  • Pathology
  • Therapy
  • European Union

Gazyva

  • $ 10000
  • January 2019
  • 40 pages

Drug Overview Gazyva (obinutuzumab; Roche/Biogen/Chugai/Nippon Shinyaku) is a third-generation, type II glycoengineered, humanized anti-CD20 monoclonal antibody (MAb) that recognizes the type II epitope ...

  • Cancer
  • Lymphoma
  • Medical Biotechnology
  • Therapy
  • European Union

Ublituximab

  • $ 10000
  • January 2019
  • 43 pages

Drug Overview Ublituximab (TG Therapeutics/LFB Biotechnologies) is an anti-CD20 monoclonal antibody, currently in late-stage trials across a range of hematological and neurological indications. CD20 is ...

  • Cancer
  • Lymphoma
  • Pathology
  • European Union
  • United States

lisocabtagene maraleucel

  • $ 10000
  • January 2019
  • 30 pages

Drug Overview Lisocabtagene maraleucel (also known as JCAR017; Celgene) will be the third autologous chimeric antigen receptor T-cell (CAR-T) therapy to reach the diffuse large B-cell lymphoma (DLBCL) ...

  • Cancer
  • Lymphoma
  • Medical Biotechnology
  • Pathology
  • European Union

Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on